Shareholder law firm launches securities fraud probe into Capricor Therapeutics after FDA advisory committee raised doubts about its heart‑failure therapy
Executive summary: Glancy Prongay Wolke & Rotter LLP announced it has commenced a securities fraud investigation into Capricor Therapeutics concerning the FDA’s review and advisory committee meeting about the company’s heart‑failure therapy. The investigation raises potential legal liability and could further depress the company’s stock, which already fell sharply after the FDA advisory committee’s skepticism.
Who is involved: Glancy Prongay Wolke & Rotter LLP (law firm), Capricor Therapeutics (NASDAQ: CAPR), the FDA advisory committee, and affected shareholders.
Likely next: Capricor may be required to preserve documents and respond to the law firm’s inquiries; the SEC could monitor the situation, and any ensuing lawsuit could lead to discovery, settlement, or trial.
Glancy Prongay Wolke & Rotter LLP said it opened an investigation on behalf of Capricor investors following the FDA’s advisory committee meeting, which questioned the statistical significance of the company’s Deramiocel therapy. The announcement comes after Capricor’s shares tumbled 60‑70% on July 27 when FDA briefing documents challenged the trial results. While the probe does not allege wrongdoing, it signals growing legal scrutiny that could lead to a class action suit and affect the company’s ability to raise capital.
What's next — scenarios
Litigation Escalation & Capital Freeze (50%)
Capricor faces severe liquidity constraints and potential dilutive financing if legal costs mount alongside investor outflows.
- Formal filing of a class-action lawsuit
- Withdrawal of institutional investors
Regulatory Reversal / Data Clarification (30%)
A favorable FDA response or supplemental data could neutralize the legal probe and initiate a rapid stock recovery.
- FDA response to company's rebuttal
- Positive sentiment from independent clinical experts
Terminal Value Erosion (20%)
Complete loss of confidence in Deramiocel clinical utility leads to a permanent impairment of the company's valuation.
- FDA non-approval decision
- Termination of strategic partnerships
What to watch
- FDA's formal decision/action letter regarding Deramiocel (next 60-90 days)
- Capricor's next quarterly cash runway update
- Legal filings from Glancy Prongay Wolke & Rotter LLP (next 30 days)
- Any unexpected secondary offering or debt issuance
Timeline
- — Pentair plc (PNR) Stockholders: Contact Robbins LLP Regarding its Ongoing Investigation (PR Newswire)
- — INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Photronics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - PLAB (PR Newswire)
- — Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm (PR Newswire)
- — Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR) (PR Newswire)
Analysis — what this means
Sectors affected
- cardiovascular biotechnology
Historical parallels
- Levi & Korsinsky announced a pending investigation into Capricor on July 29, 2026 after a 60‑70% stock drop following FDA briefing doubts
Key entities
Sources
- Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm — PR Newswire
- Pentair plc (PNR) Stockholders: Contact Robbins LLP Regarding its Ongoing Investigation — PR Newswire
- INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Photronics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - PLAB — PR Newswire
- Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR) — PR Newswire
Related cases
- AEVEX Corp. faces imminent securities class action deadline as investors seek lead plaintiff status
- Robbins Geller Rudman & Dowd LLP sets October 13, 2026 deadline for investors to seek lead plaintiff role in UWM Holdings class action
- Regeneron faces imminent lead‑plaintiff deadline in a securities class action that could trigger legal costs and stock volatility
- Law firm Levi & Korsinsky launches investigation into Meridian Corporation for potential breach of fiduciary duties
- Ademi LLP is examining whether the proposed buyout of WaFd, Inc. fairly values the company, noting current shareholders would own just 40.8% of the combined entity
- Edelson Lechtzin LLP launches investigation into Hibbett Retail data breach, signaling potential class action exposure